Chimerix, which is developing a potent antiviral drug for use in stem cell transplants, raised $102 million by offering 7.3 million shares at $14, within the range of $13 to $15. The company had originally planned to sell 6.1 million shares before upsizing the deal by 20%. Aisling Capital agreed to purchase $15 million of shares on the IPO (15% of the deal). Chimerix plans to list on the NASDAQ under the symbol CMRX. Morgan Stanley and Cowen & Company acted as lead managers on the deal.
